Sprout pharmaceuticals is a company that was created by women for women. It was founded on January 1st 2011 by Cindy Eckert and quickly made a name for itself with its ground-breaking research into women's health and female sexual dysfunction. By August 2015, their flagship drug Addyi was granted FDA approval and introduced to the market as the world's first treatment for hypoactive sexual desire disorder (HSDD). Since then, Sprout Pharmaceuticals has gone on to establish itself as a market leader in women's health.
The sole goal of Sprout Pharmaceuticals is to support women's sexual health. Patient advocacy, innovation, and empowerment are at the foundation of their beliefs. Believing that sexual well-being is an essential component of general health, they are committed to provide a voice to women with Hypoactive Sexual Desire Disorder (HSDD) through research, education, and the development of authorized treatments.
At Sprout Pharmaceuticals, innovation is based on research and development. RD is intensely concentrated on filling the important but often overlooked gap in women's sexual health. Sprout's work transforms a previously misunderstood ailment into a recognized and treated medical concern by pioneering and navigating rigorous clinical trials, which offers the critical scientific validation needed to bring an effective, FDA-approved medication to the market.
Sprout Pharmaceuticals secured the first-ever FDA approval for Addyi (flibanserin) to treat Hypoactive Sexual Desire Disorder (HSDD), validating it as a medical condition. While the rights to Addyi are now licensed, Sprout's ground-breaking work never stops. They continue to research and develop new and innovative solutions that champion women's health. Choosing Sprout is choosing to prioritise female sexual health. Their range of licensed and approved treatments have changed the way FSD is viewed and offer hope to millions of women around the world.
